OncoSil Medical Past Earnings Performance

Past criteria checks 0/6

OncoSil Medical's earnings have been declining at an average annual rate of -11.6%, while the Life Sciences industry saw earnings growing at 19.7% annually. Revenues have been declining at an average rate of 29% per year.

Key information

-11.6%

Earnings growth rate

4.2%

EPS growth rate

Life Sciences Industry Growth19.7%
Revenue growth rate-29.0%
Return on equity-286.8%
Net Margin-901.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

May 24
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Feb 03
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Oct 20
Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

May 13
OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Mar 21
OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

Jan 26
We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04
How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Revenue & Expenses Breakdown

How OncoSil Medical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:OSL Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231-1283
30 Sep 231-1283
30 Jun 231-1183
31 Mar 231-1183
31 Dec 221-1183
30 Sep 221-1183
30 Jun 221-1182
31 Mar 221-1192
31 Dec 211-1193
30 Sep 211-1183
30 Jun 211-1083
31 Mar 212-863
31 Dec 202-653
30 Sep 202-544
30 Jun 203-434
31 Mar 203-654
31 Dec 193-764
30 Sep 193-865
30 Jun 194-976
31 Mar 194-976
31 Dec 184-977
30 Sep 184-976
30 Jun 184-976
31 Mar 184-876
31 Dec 174-876
30 Sep 174-875
30 Jun 174-774
31 Mar 173-773
31 Dec 162-672
30 Sep 163-563
30 Jun 164-563
31 Mar 164-353
31 Dec 154-243
30 Sep 153-333
30 Jun 153-333
31 Mar 152-533
31 Dec 142-733
30 Sep 141-732
30 Jun 140-741
31 Mar 140-531
31 Dec 130-320
30 Sep 130-210

Quality Earnings: OSL is currently unprofitable.

Growing Profit Margin: OSL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OSL is unprofitable, and losses have increased over the past 5 years at a rate of 11.6% per year.

Accelerating Growth: Unable to compare OSL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OSL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.9%).


Return on Equity

High ROE: OSL has a negative Return on Equity (-286.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.